PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
March 4, 2026Journal of Clinical Oncology

Predictors of early termination in phase 2–3 genitourinary oncology trials: A two-decade analysis of clinicaltrials.gov.

View Full Paper
Ask AI
Bookmark
Share

Authors

KMKamil MalshySCSuiyue CuiZCZijing Cheng

Discussion

Loading...

Member takes

Overview

Analysis reveals trial predictors impacting completion rates in phase 2–3 genitourinary oncology trials, suggesting operational improvements.

Key Points

  • This analysis aims to identify factors influencing early termination versus completion in phase 2–3 genitourinary oncology trials.
  • Analyzed clinical trials registered on ClinicalTrials.gov from 2005 to 2025.
  • Included interventional Phase 2–3 GU oncology trials conducted in U.S. adults.
  • Evaluated predictors like trial design, sponsor type, intervention category, and geographic scope using multivariable logistic regression.
  • Among 1,597 analyzed trials, 445 (27.9%) were terminated, mainly due to poor accrual.
  • Prostate cancer trials had a higher completion rate compared to bladder trials (OR 1.84).
  • Trials that were multisite (OR 1.58) and multinational (OR 1.73) had higher completion odds.
  • Randomized trials (OR 0.67) and those with a DMC (OR 0.69) were linked to higher risks of early termination.

Cite This Study

Malshy et al. (2026) studied this question.

synapsesocial.com/papers/69a7cd7ed48f933b5eed9d31https://doi.org/10.1200/jco.2026.44.7_suppl.331
View Full Paper
Ask AI
Bookmark
Share